HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy - Archive ouverte HAL
Article Dans Une Revue American Journal of Hematology Année : 2022

HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy

Nicolas Chuvin
Rasha Boulos
Yann Estornes

Résumé

Human endogenous retroviruses (HERVs) represent 8% of the human genome. The expression of HERVs and their immune impact have not been extensively studied in Acute Myeloid Leukemia (AML). In this study, we used a reference of 14 968 HERV functional units to provide a thorough analysis of HERV expression in normal and AML bone marrow cells. We show that the HERV retrotranscriptome accurately characterizes normal and leukemic cell subpopulations, including leukemia stem cells, in line with different epigenetic profiles. We then show that HERV expression delineates AML subtypes with different prognoses. We finally propose a method to select and prioritize CD8 + T cell epitopes derived from AML-specific HERVs and we show that lymphocytes infiltrating patient bone marrow at diagnosis contain naturally
Fichier principal
Vignette du fichier
Alcazer Herv 2022-AJH-97-1200.pdf (6.19 Mo) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-03855460 , version 1 (16-11-2022)

Identifiants

Citer

Vincent Alcazer, Paola Bonaventura, Laurie Tonon, Emilie Michel, Virginie Mutez, et al.. HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy. American Journal of Hematology, 2022, 97 (9), pp.1200-1214. ⟨10.1002/ajh.26647⟩. ⟨hal-03855460⟩
268 Consultations
135 Téléchargements

Altmetric

Partager

More